| Document |
Document Title |
|
WO/2014/018979A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates general...
|
|
WO/2014/014035A1 |
The invention pertains to a novel pyrophosphoric acid ester compound represented by formula (1) and a bisphosphoric acid ester compound represented by formula (2). In the formulas, R is an aryl group, organic silyl group, or halogen atom...
|
|
WO/2014/013512A1 |
Disclosed is one pot process of the preparation of 2,3-dihydroxy benzonitrile from 2,3-dialkoxy benzoic acid without prior isolation of the intermediates. Further disclosed is the preparation of 2,3-dihydroxy benzonitrile by dealkylation...
|
|
WO/2014/015276A1 |
The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure: Formula (I).
|
|
WO/2014/009767A1 |
The present invention relates to an improved and one-pot process for the preparation of 1-Aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers of formula (I) or its pharmaceutically acceptable salt thereof wherein ...
|
|
WO/2014/008350A1 |
The present invention provides a process for preparing a bicyclic amine derivative of the for-mula (Ia) or (Ib), (Formulae (Ia) (Ib)) comprising the rhodium-catalyzed asymmetric hydrogenation of an enamine of the formula (II), (Formula (...
|
|
WO/2014/002101A1 |
The invention relates to compounds for reducing or inhibiting a biological function mediated by LIMK1 or LIMK2, wherein the compounds are selected to bind the ATP-binding site and/or the substrate-binding site of LIMK.
|
|
WO/2014/001939A1 |
An improved process for the preparation of agomelatine of formula (I) and a new process for the preparation of crystalline form I of agomelatine are provided.
|
|
WO/2014/002967A1 |
Provided is a 4,6-hexadecadiene-2,4-dicarboxylic acid derivative or pharmaceutically acceptable salt thereof or the like, having anti-tumour activity and represented by general formula (I): [in the formula, R1 represents a hydroxy, –OR...
|
|
WO/2013/181697A1 |
The present invention relates to compounds that can be used link substrates to molecules, typically for biological applications such as imaging and the like. The compounds contain a cyclooctyne which is joined, via a linking group, to a ...
|
|
WO/2013/181332A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donor...
|
|
WO/2013/180649A1 |
Compositions for reducing the aggregate content of a protein preparation include a first substrate having a first surface-bound ligand possessing a metal affinity functionality and a second surface-bound ligand optionally provided on a s...
|
|
WO/2013/172292A1 |
An aqueous gel that is prepared by gelling polymer components, said polymer components comprising polymer A, which is obtained by polymerizing a monomer component containing a betaine monomer represented by formula (I) [wherein: R1 repre...
|
|
WO/2013/173707A1 |
Isolated metabolites of (1 R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]- methyl]propanamide, methods for their use, and compositions containing the metabolites.
|
|
WO/2013/171492A1 |
A peracid bleaching species is formed in situ in aqueous wash liquor by reaction of a peroxygen bleach precursor, such as perborate or percarbonate, and a bleach activator. The bleach activator is an acetylated ethylene diamine, that com...
|
|
WO/2013/167987A1 |
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...
|
|
WO/2013/168021A1 |
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...
|
|
WO/2013/168925A1 |
The present invention relates to a nanoparticle-based nitroaromatic explosive sensor for detecting nitroaromatic compounds, more specifically to stably detecting explosives in an aqueous solution by introducing, on the surface of the nan...
|
|
WO/2013/169231A1 |
Synergistic antimicrobial compositions are provided by combining effective amounts of Na-long chain alkanoyi di basic amino acid alkyl ester salts with glycerol monofatty acid esters resulting more effective anti-microbials and food pres...
|
|
WO/2013/164326A1 |
The compounds of formula (1), in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
|
|
WO/2013/165606A1 |
Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovas...
|
|
WO/2013/163675A1 |
The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula (I), as defined in the specification. The invention also rela...
|
|
WO/2013/160728A1 |
Compounds of formula (I) wherein the groups are as defined in the description, are used as medicaments, in particular for the treatment of a disease selected from the group consisting of: cognitive impairment, memory dysfunction, neurode...
|
|
WO/2013/161642A1 |
A photochromic curable composition of the present invention is characterized by containing, as (A) radically polymerizable monomer components, (A1) a (meth)acryl amide polymerizable monomer which has 2-6 (meth)acryloyloxy groups and 2-6 ...
|
|
WO/2013/161480A1 |
Provided are: an epoxy resin curing agent that can cause the realization of high gas barrier properties and favorable adhesion to various plastics, particularly polyesters; an epoxy resin composition; a gas barrier adhesive agent contain...
|
|
WO/2013/159736A1 |
Disclosed are a monofluoro cyclopropane compound, and preparation method and uses thereof. The structure of the monofluoro cyclopropane compound is as represented by formula I, wherein R1, R2, Ra, and formula II are as defined in the spe...
|
|
WO/2013/162298A1 |
The present invention relates to novel beta-alanine derivatives, to the pharmaceutically acceptable salts thereof, and to a pharmaceutical composition comprising same as an active ingredient. The novel beta-alanine derivatives and pharma...
|
|
WO/2013/153873A1 |
A photosensitive compound represented by formula (1) or formula (2). (Chemical formula 1) (In formula (1) and formula (2), n is an integer of 1-3; R1 is a linear or branched alkyl group having 1-6 carbon atoms or an alkylene group having...
|
|
WO/2013/150072A1 |
The present invention concerns pro-drugs of 1-(2-halo-biphenyl-4-yl) alkanecarboxylic acids, pharmaceutical compositions thereof, a process for their preparation and their use for preventing and/or treating neurodegenerative diseases, im...
|
|
WO/2013/148997A1 |
Compounds represented by the formula and their edible salts, and edible compositions containing same wherein R1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 do...
|
|
WO/2013/149025A1 |
A flavour composition comprising a compound of formula (I) edible salts thereof, wherein R1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double bonds, R1 toget...
|
|
WO/2013/149012A1 |
A flavour composition comprising a compound of formula (I) represented by the formula (I) and edible salts thereof, wherein R1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms...
|
|
WO/2013/148991A1 |
A flavour composition comprising a compound according to the formula (I) edible salts thereof, wherein R1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double b...
|
|
WO/2013/144101A1 |
The present invention relates to a novel process for preparing cis-alkoxy-substituted spirocyclic phenylacetylamino acid esters and cis-alkoxy-substituted spirocyclic 1-H-pyrrolidine-2,4-dione derivatives and also novel intermediates and...
|
|
WO/2013/144979A1 |
The present invention relates to an improved process for the preparation of Aliskiren and its pharmaceutically acceptable salts comprising reducing the compound of Formula-Z in presence of catalyst and ammonia. The present invention furt...
|
|
WO/2013/143811A1 |
Compounds of the formula (I), in which the substituents are as defined in claim 1,are suitable for use as nematicides.
|
|
WO/2013/146437A1 |
[Problem] To provide a novel compound that is useful as an agent for preventing/treating cancer. [Solution] One aspect of the present invention provides a compound expressed by the chemical formula (1) or a pharmaceutically permissible s...
|
|
WO/2013/135511A1 |
The present invention primarily relates to the amides of Formulae (I) and (II) (see below) and mixtures thereof, and to the use thereof as flavoring agents. The compounds in accordance with the present invention are suitable for producin...
|
|
WO/2013/136061A1 |
New polymorphic form of a long-acting beta-2 adrenoceptor agonist A new polymorphic form of arformoterol tartrate, designated as form D, is provided and which is characterised by at least one of the following: (i) a powder X-ray diffract...
|
|
WO/2013/132991A1 |
A liquid crystal composition which contains liquid crystal molecules and a compound represented by the formula shown below. If this liquid crystal composition is subjected to crystal alignment and formed into a film, the resulting film h...
|
|
WO/2013/131043A1 |
The present invention provides organic molecules and methods thereof for reactions between organoboron reagents and double bonds, such as imines or carbonyls, to stereoselectively provide chiral products including amines and alcohols, en...
|
|
WO/2013/128927A1 |
The present invention provides a novel androgen receptor (AR) antagonist useful for the treatment of prostate cancer or the like. Specifically, the AR antagonist is a compound represented by formula (I) [wherein X represents -X1-CONH-X2-...
|
|
WO/2013/127841A1 |
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are defined in the detailed description and claims. In addition, the present invention relates to method...
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/123456A1 |
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutatio...
|
|
WO/2013/123222A1 |
The invention provides processes for preparing intermediates useful for preparing compounds of the formula (IV): or a tautomer or salt thereof, where R1-R5, a, b, X and P2, are as defined in the specification.
|
|
WO/2013/120257A1 |
Provided is a method for synthesizing a laevo-p-hydroxyphenylglycine compound, comprising: (1) subjecting an amine compound with a glyoxylic acid ester compound to a nucleophilic addition reaction; subjecting the product obtained in step...
|
|
WO/2013/118751A1 |
An amide compound can be produced efficiently by reacting a carboxylic acid ester compound and a primary or secondary monoamine compound in the presence of a catalyst obtained by bonding at least one alkoxy group to a metal or semimetal ...
|
|
WO/2013/118896A1 |
Provided is a compound with which it is possible to gelatinize various aqueous compositions containing salt, acid, and such. A basic amino acid derivative represented by formula (1) (refer to the description for information regarding eac...
|
|
WO/2013/117846A1 |
The invention relates to a cosmetic composition including at least one compound of formula (I), used alone or as part of a mixture, or one of the salts, hydrates, acetals, or hemiacetals thereof, where Y is an OR, NRR', or R group with R...
|
